Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04880863
Status:
COMPLETED
Last Update Posted:
2024-02-22
First Post:
2021-05-03
Brief Title:
Naptumomab Estafenatox NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Sponsor:
NeoTX Therapeutics Ltd
Organization:
NeoTX Therapeutics Ltd